- Regulatory Status
- RUO
- Other Names
- A Proliferation Inducing Ligand (APRIL), TNFSF13, CD256, TALL2, TRDL1
Cat # | Size | Price | Quantity Check Availability | ||
---|---|---|---|---|---|
568004 | 25 µg | $580.00 | |||
568006 | 100 µg | $995.00 |
APRIL (A Proliferation-Inducing Ligand), also known as TNFSF13, is a member of the TNF superfamily of ligands and stimulates cell proliferation. APRIL shares 30% amino acid sequence identity with BAFF. APRIL is cleaved intracellularly by furin and is believed to exist mainly in a secreted, soluble form. As with most other TNF family members, APRIL exists as a functional homotrimer (total MW = 90 kD). In conjunction with BAFF, APRIL binds cell-surface receptors, BCMA and TACI to exert T cell-dependent and -independent antibody secretion and B cell differentiation. In addition, APRIL possesses a heparan sulfate proteoglycan binding domain and has been demonstrated to bind to proteoglycans on the cell surface in vitro and in situ.
APRIL is a potential biomarker and is most well-known for tumor proliferation effects. For certain cancers, APRIL levels are elevated in serum while for other cancers, higher tissue expression levels of APRIL have been observed. In addition, APRIL is a potential biomarker for certain autoimmune diseases. Recently, recombinant TACI has been brought to clinical trials as a neutralization drug against APRIL and BAFF for the treatment of systemic lupus erythematosus (SLE). Furthermore, besides forming homotrimers, APRIL can also form functional heterotrimers with BAFF. Although the stoichiometric relationship of the protomeric units is still unclear, it appears that these heterotrimers are significant in that they are elevated in the serum of certain autoimmune patients. APRIL also forms an endogenous chimeric protein with another related protein, TWEAK, effectively called TWE-PRIL. It is believed that TWE-PRIL is membrane bound and consists of the N-terminus of TWEAK with its transmembrane domain, and the C-terminus of APRIL with its receptor binding domain.
Product Details
- Source
- Human TNFSF13, amino acid Ala105-Leu250 (Accession# O75888.1), with N-terminal HA tag, followed with GCN4tri and a 3(GGGGS) linker, was expressed in CHO cells.
- Molecular Mass
- The 202 amino acid recombinant protein has a predicted molecular mass of approximately 22.19 kD. The DTT-reduced and non-reduced protein shall migrate at approximately 20 – 40 kD by SDS-PAGE. The predicted N-terminal amino acid is Tyr.
- Purity
- > 95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 20 mM Tris, 500 mM NaCl, pH 8.0
- Concentration
- 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 μg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Human TNFSF13 induces mouse B cell proliferation in a dose-dependent manner. The ED50 is 0.1 - 0.5 ng/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Trimer
- Distribution
-
T cells, B cells, dendritic cells, monocytes, and macrophages
- Function
- Induces proliferation of T and B cells, promotes IgA class switching and downregulates T-cell dependent antibody responses, regulates the growth of a variety of tumor cells
- Interaction
- T cells, B cells, cancer cells
- Ligand/Receptor
- TNFRSF13b (TACI), TNFRSF17 (BCMA)
- Bioactivity
- ED50 = 0.1 – 0.5 ng/mL as determined by the dose-dependent stimulation of mouse B cell proliferation.
- Cell Type
- B cells, Dendritic cells, Macrophages, Monocytes, T cells
- Biology Area
- Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Cell Proliferation and Viability, Signal Transduction
- Molecular Family
- Cytokines/Chemokines, Soluble Receptors
- Antigen References
-
- Hymowitz S, et al. 2005. J Biol Chem. 280:7218-27.
- Ingold K, et al. 2005. J Exp Med. 201:1375-83.
- Good K, et al. 2009. J Immunol. 182:890-901.
- Bossen C, et al. 2008. Blood. 111:1004-12.
- Bossen C, et al. 2006. J Biol Chem. 281:13964-71.
- Pradet-Balade B, et al. 2002. EMBO J. 21:5711-20.
- Hahne M, et al. 1998. J Exp Med. 188:1185-90.
- Medema JP, et al. 2003. Cell Death Differ. 10:1121-5.
- Planelles L, et al. 2007. Haematologica. 92:1284-5.
- Dillon SR, et al. 2010. Arthritis Res. Ther 12:R48.
- Wallweber H, et al. 2004. J Mol Biol. 343:283-90.
- Chen Y, et al 2011. PLoS ONE. 6:e22202.
- Roschke V, et al. 2002. J Immunol. 169:4314-21.
- Gene ID
- 8741 View all products for this Gene ID
- UniProt
- View information about APRIL/TNFSF13 on UniProt.org